Business expansion into cells derived from umbilical cord and other perinatal tissues
First written in FY2021. 11 of 14 entries say "Advanced", first in FY2022. Latest entry: 2026-08-06.
1 other company's latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Number of cord blood and umbilical cord specimens stored by the company, including revenue-generating specimens」
For the fiscal year ending March 2026, new stored specimens totaled 7,357 cord blood specimens and 5,062 umbilical cord specimens, with cumulative totals of 102,040 and 12,135 specimens, respectively, indicating progress in the expansion into perinatal tissue-derived cells, including umbilical cord cells. - 2026-05-13AdvancedResults presentation
「More than 12,000 umbilical cord specimens stored」
Cumulative umbilical cord storage exceeded 12,000 specimens, demonstrating expansion of the business based on cells derived from perinatal tissues in addition to cord blood. - FY2026-H1AdvancedAnnual report
「The new HOPECELL storage plan, introduced in November 2024, is a service that collects and stores both cord blood and umbilical cord tissue, enabling more reliable storage of valuable cells available only at childbirth. Its market penetration is progressing steadily. As a result, average revenue per customer increased compared with the former plan, while new umbilical cord storage cases rose approximately 2.1 times year on year, representing substantial growth.」
The storage business covering umbilical cord tissue in addition to cord blood progressed as HOPECELL gained market penetration and new storage cases increased. - FY2025AdvancedAnnual report
「We are actively promoting medical development using autologous umbilical cord tissue and working to increase the value of storing umbilical cord tissue.」
New annual umbilical cord storage specimens totaled 4,745, bringing the cumulative total to 13,210. Medical development using autologous umbilical cord tissue continues to be promoted as a means of expanding storage demand. - FY2025-H1AdvancedAnnual report
「For “umbilical cord,” the launch in June last year of the “Family Conditioned Medium” production service, which produces cultured conditioned medium containing growth factors that promote tissue regeneration and intercellular signaling substances such as exosomes for families who have stored the tissue, raised the umbilical cord storage rate among cord blood customers to more than 50%. Inquiries and applications for the service are also steadily increasing.」
In addition to the umbilical cord storage service, the Family Conditioned Medium production service was launched, raising the umbilical cord storage rate among cord blood customers to more than 50%. - FY2024-Q3RestatedAnnual report
「We operate a cell banking business involving perinatal tissue-derived cells, including “cord blood” and “umbilical cord,” for regenerative medicine and cell therapy, and develop new treatments and regenerative medicine products using these cells.」
We continue to operate a banking business covering perinatal tissue-derived cells, including umbilical cord cells, in addition to cord blood, and to develop treatments and products using these cells. - FY2024-Q2AdvancedAnnual report
「The umbilical cord storage service, launched in April 2021 as Japan's first such service, continued to grow steadily. As a result, during the six months ended September 30, quarterly revenue, operating profit, ordinary profit and net income all reached record highs, and progress exceeded the full-year budget in revenue and every profit category.」
The company explained that steady growth in the umbilical cord storage service led to record quarterly revenue, operating profit, ordinary profit and net income, as well as progress exceeding the full-year budget. - FY2024-Q1AdvancedAnnual report
「For the umbilical cord storage service, launched in April 2021 as Japan's first such service, demand for storage has increased since June this year following the launch of Japan's first family cultured conditioned medium production service, which cultures umbilical cord tissue and produces and provides the conditioned medium to families using the storage service. The storage rate has consequently exceeded the plan.」
Based on the umbilical cord storage service, a new service to produce and provide conditioned medium from cultured umbilical cord tissue to families using the storage service was launched in June 2023, and the storage rate exceeded the plan. - FY2023AdvancedAnnual report
「Fiscal year ended March 2023 7,564 specimens 77,660 specimens 2,907 specimens 4,418 specimens」
In addition to cord blood, new umbilical cord tissue storage specimens totaled 2,907, bringing the cumulative total to 4,418, indicating progress in the expansion into perinatal tissue-derived cells in the full-year results. - FY2023-Q1RestatedAnnual report
「We operate a cell banking business involving perinatal tissue-derived cells, including “cord blood” and “umbilical cord,” for regenerative medicine and cell therapy, develop new treatments and regenerative medicine products using these cells, and conduct business development and investment in regenerative medicine, fertility treatment, childbirth, childcare and other fields based on these business platforms.」
The company continues to expand its business to cover perinatal tissue-derived cells, including umbilical cord cells, in addition to cord blood. No new target areas or launch timing were specified. - FY2022AdvancedAnnual report
「This was due to the launch of the umbilical cord storage service from the current fiscal year.」
The expansion into umbilical cord tissue collection and storage was incorporated into full-year results, with 1,511 new and 1,511 cumulative umbilical cord specimens stored. - FY2021First statedAnnual report
「We will expand our business by working with medical and research institutions to collect and store cells derived from tissues associated with childbirth, including “umbilical cord” tissue, known as perinatal tissue-derived cells.」
The company plans to expand its business beyond cord blood to the collection and storage of tissues derived from childbirth.